Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (
131I) and lutetium (
177Lu) minretumomab, for example, were shown to induce
human anti-mouse antibodies; no tumour response was observed in Phase I and II
clinical trials.[5]
^Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, et al. (2006). "Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)". Bioconjugate Chemistry. 17 (2): 410–8.
doi:
10.1021/bc0503521.
PMID16536473.
^Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, et al. (November 1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay". Cancer Research. 56 (22): 5293–8.
PMID8912871.